SEOUL — Modern insomnia care is undergoing a conceptual transformation. Rather than relying on traditional sedatives that chemically force the brain into sleep, medical professionals are increasingly pointing toward target-based therapies that quiet excessive neurological alertness.

Beyond a Secondary Symptom

Historically, sleep disorders were frequently dismissed as side effects or secondary symptoms of other underlying health conditions. However, clinical consensus has shifted dramatically over the past decade. The International Classification of Sleep Disorders formally recognizes insomnia as an independent medical condition, categorizing cases into acute and chronic based on a three-month threshold.

Experts note that insomnia manifests in complex ways. While some patients experience a genuine deficit in sleep quantity due to acute stress, others suffer from poor sleep quality—characterized by fragmented sleep cycles and low sleep density—even if their total hours in bed appear adequate. Regardless of the exact pattern, untreated chronic insomnia severely degrades daytime functioning, driving chronic fatigue, cognitive decline, and mood disturbances.

The Limits of Conventional Care

For chronic insomnia, Cognitive Behavioral Therapy for Insomnia (CBT-I) remains the gold standard. By restructuring sleep habits, lowering hyperarousal, and optimizing time spent in bed, CBT-I addresses the root behavioral drivers of sleeplessness.

Yet, practical hurdles remain. In fast-paced healthcare environments, delivering comprehensive behavioral therapy is often constrained by a lack of time and specialized personnel. Consequently, physicians have historically relied heavily on traditional sedative-hypnotics to help patients fall asleep quickly.

However, conventional sleeping pills come with notable trade-offs. By globally depressing brain activity, these medications frequently cause next-day grogginess, residual daytime sleepiness, and parasomnias like sleepwalking. For elderly populations, even mild sedative effects can drastically elevate the risk of accidental falls and injuries.

A New Class of Therapeutics: Targeting Orexin

To address these limitations, treatment priorities have evolved. Modern insomnia management evaluates success not just by how fast a patient falls asleep, but by their ability to function clearly the following day without residual fatigue or chemical dependency risks.

This shift has fueled the adoption of Dual Orexin Receptor Antagonists (DORAs). Orexin is a key neurotransmitter responsible for maintaining wakefulness and arousal in the brain. While a deficiency in orexin leads to narcolepsy, selectively inhibiting excessive orexin signaling allows physicians to dial down hyper-arousal rather than brute-force sedation.

Newer DORA-class medications, such as lemborexant, have demonstrated strong safety and tolerability profiles in large-scale clinical trials. Medical specialists suggest that these targeted options offer a safer profile for vulnerable demographics, such as older adults.

A Comprehensive Approach Is Still Required

Despite pharmaceutical advancements, sleep specialists emphasize that drugs are only one tool in a larger toolkit. CBT-I remains fundamental to long-term recovery for chronic sufferers.

Patients struggling with persistent sleep disturbances are advised to seek professional medical evaluation. Because individuals often misjudge their actual sleep duration versus perceived sleep, objective diagnostic assessments are vital to uncovering the root causes and establishing a personalized, sustainable treatment plan.

[Copyright (c) Global Economic Times. All Rights Reserved.]